Cyted Health

Redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.

[Cyted Health @CytedHealth]

Our EndoSign® cell collection device has received 510(k) clearance from the FDA, enabling earlier and more efficient detection of esophageal pre-cancer and other conditions.

#DetectToProtect #FDA

[Cyted Health @CytedHealth]

Clinicians are being urged to reduce low yield endoscopies, and earlier risk stratification could be key to this.

EndoSign® capsule sponge testing offers minimally invasive triage to support targeted referral.

Learn more: https://t.co/Kn5wUCn5S3

#Endoscopy #BarrettsOesophagus

[Cyted Health @CytedHealth]

What is the difference between capsule endoscopy and capsule sponge technology?

Explore more of our frequently asked questions:

#UpperGI #Diagnostics #OesophagealCancer #Reflux #Endoscopy

[Cyted Health @CytedHealth]

31-MarYou may know EndoSign® as the ‘pill on a string’ – but what is it?

A minimally invasive triage tool that collects oesophageal cells to assess #reflux and Barrett’s risk.

Learn more: https://t.co/Kn5wUCn5S3

#OesophagealCancer #Reflux

[Cyted Health @CytedHealth]

Oesophageal cancer is often diagnosed late, impacting outcomes. 5 year survival can be ~95 % when detected early, but reduces to 5-40 % at advanced stages.

EndoSign® enables minimally invasive risk stratification for targeted referrals.

Learn more: https://t.co/Kn5wUCmy2v

[Cyted Health @CytedHealth]

Up to 75 % of UK #gastroscopies may be performed in patients with <1 % cancer risk.

Earlier risk stratification could reduce low yield procedures. EndoSign® supports minimally invasive assessment to better target #endoscopy.

Learn more: https://t.co/Kn5wUCn5S3

[Cyted Health @CytedHealth]

What do patients think of EndoSign® capsule sponge test?

Read more about the patient experience here:

#HeartburnHealthCheck #OesophagealCancer #EarlyDiagnosis #NHSInnovation

[Frontline Gastro @FrontGastro_BMJ]

💭 What does long-term follow-up 📊 on low-risk patients w/ Barrett's esophagus triaged with 🧽 capsule sponge look like❓

✅ Check out these interesting and reassuring results from a study (relatively small sample size) @FrontGastro_BMJ 🖇️ https://t.co/nlAk65gzxh that showed
↪️ No significant differences in the detection of dysplasia or cancer in patients with follow-up endoscopy vs repeat capsule sponge testing and endoscopy
↪️ All cases w/ HGD and cancer were detected by repeat capsule sponge testing w/ positive biomarkers (atypia and p53)

👏 Thank you to authors @siobhan_chien @GastronautIan Paul Glen Gavin Bryce Michael Miller Neil Cruickshank Andrew Crumley Jonathan Fletcher Ivan Gunjaca Perminder Phull @JKApollos Kevin Robertson Grant M Fullarton

@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @ulstergastro #GITwitter

[Cyted Health @CytedHealth]

1 in 100 people in the UK may require surveillance for Barrett’s oesophagus, creating sustained #endoscopy demand.

EndoSign® provides minimally invasive risk stratification, helping prioritise those most likely to benefit from endoscopy.

Learn more: https://t.co/Kn5wUCmy2v

[Cyted Health @CytedHealth]

@NICEcomms announced that the capsule sponge test will be one of the first technologies to be in its new National #Healthtech Access Programme.

We welcome this focus on technologies that support early detection.

[Cyted Health @CytedHealth]

@NICEComms announced that the capsule sponge test will be one of the first technologies to be in its new National #Healthtech Access Programme.
We welcome this focus on technologies that support early detection.

[Cyted Health @CytedHealth]

@NICEcomms announced that the capsule sponge test will be one of the first technologies to be in its new National #Healthtech Access Programme.

We welcome this focus on technologies that support early detection.

Read more: https://t.co/iW01mG9HPu

[Cyted Health @CytedHealth]

Endoscopy demand in the NHS is rising. Capacity is finite.
Non-endoscopic diagnostics such as EndoSign® can support risk stratification, helping ensure endoscopy is reserved for patients who need it most.

https://t.co/OazOIEnCvT

#CancerInnovation #EarlyDetection

[Cyted Health @CytedHealth]

The National Cancer Plan for England includes piloting capsule sponge heartburn health checks in pharmacies.

Earlier, minimally invasive assessment may reduce unnecessary endoscopy referrals.

Discover EndoSign®: https://t.co/yKDWSNmspL

#NationalCancerPlan #EarlyDiagnosis

[GastroAGI @GastroAGI]

🧪 Capsule Sponge Triage in Reflux — Can We Reduce Unnecessary Endoscopy?

4-year prospective cohort, 871 patients.

Key findings:
• 88% adequate samples
• 62% avoided endoscopy
• Abnormal CS (~10%) strongly predicted significant pathology
• PPV for Barrett’s: 43.5%
• NPV: 98.2%
• >97% patient acceptability

Detected: 1 cancer, 2 dysplasia, 34 Barrett’s cases.
Long-term follow-up confirmed safety.

Takeaway: Capsule sponge safely stratifies reflux patients, increases diagnostic yield, and optimizes endoscopy resources.

#GERD #BarrettsEsophagus #Endoscopy #GIInnovation #GastroAGI

[Cyted Health @CytedHealth]

How do we detect Barrett’s oesophagus earlier without overwhelming endoscopy?

EndoSign® capsule sponge testing enables early risk stratification, supporting more efficient use of NHS endoscopy capacity.

Discover more: https://t.co/OazOIEnCvT

#BarrettsOesophagus #NHS

[Cyted Health @CytedHealth]

Expanding NHS FIT screening is a major step for early bowel cancer detection. But rising referrals mean #endoscopy capacity must be protected. Triage tools such as EndoSign® for oesophageal risk could help free capacity for bowel cancer patients.

https://t.co/OazOIEnCvT

[Cyted Health @CytedHealth]

For Oesophageal Cancer Awareness Month, we are sharing Eddie’s story - a powerful reminder of why early detection matters.

After decades of heartburn, and no new symptoms, the EndoSign® test helped catch his cancer early. Watch here: https://t.co/OYQAYQj8Qz

[Cyted Health @CytedHealth]

Great to see the National Cancer Plan backing proven diagnostics like the EndoSign® capsule sponge test.

It’s already used across the NHS—now national policy can help end postcode variation and ensure more patients benefit from #earlierdiagnosis.

https://t.co/76kpMKhNLB

[Cyted Health @CytedHealth]

We've done it again! Cyted Health has been shortlisted for the @HSJnews Independent Healthcare Providers Awards 2026, this time in the Best Provider of Community and Primary Care category for the #CYTOPRIME2 project. Thank you to all involved! https://t.co/xrANOzKTJA

[Frontline Gastro @FrontGastro_BMJ]

🚨 🗣️ Fantastic new original research from the CYTOPRIME 2 study 💥. Thanks to @DrDanielleMorr1 @CytedHealth and team for demonstrating that capsule sponge testing 🧽 is a practical and scalable approach to earlier detection of Barrett's oesophagus and oesophageal cancer 👏 .

Should we be implementing this in the community as a screening test for patients with GORD 🤔 💭 ?!

https://t.co/8FkmIkccky

@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BASLedu @BSGtrainees @WorldGastroOrg @ulstergastro @pancreatitis_nl @SEEDendoscopia @EASLedu @AmCollegeGastro @Aegastro @SAGES_updates @UHSEndoscopy @WAGE_media

#GITwitter #gastroenterology #Endoscopy #MedEd